What question did this study set out to answer?

To quantitatively evaluate nanoscale intercellular PD-1/PD-L1 interactions in patient tumor tissues to improve clinical stratification for immune checkpoint inhibition.

August 27, 2020Cancer ResearchOpen Access

High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment

View Full Paper

Ask AI

Bookmark

Authors

LSLissete Sánchez‐MagranerFastbase Solutions (Spain)JMJames MilesIkerbasque CBClaire L. BakerIkerbasque

Discussion

Member takes

Implication

Translational cohort study reveals reduced survival in metastatic lung cancer patients with low PD-1/PD-L1 binding, indicating physical checkpoint interaction predicts immunotherapy response.

Key Points

To quantitatively evaluate nanoscale intercellular PD-1/PD-L1 interactions in patient tumor tissues to improve clinical stratification for immune checkpoint inhibition.
Applied a high-resolution quantitative imaging assay capable of detecting intercellular protein-protein interactions occurring at distances of 10 nm or less in patient tumor specimens.
Assessed interaction heterogeneity and clinical outcomes across multiple patient cohorts, including malignant melanoma and anti-PD-1-treated metastatic non-small cell lung cancer.
Observed marked intercancer, interpatient, and intratumoral heterogeneity in checkpoint binding, with PD-1/PD-L1 interaction levels showing no correlation to standard clinical PD-L1 expression scores in melanoma.
Identified significantly worsened survival among anti-PD-1-treated metastatic non-small cell lung cancer patients exhibiting low PD-1/PD-L1 interaction levels compared to those with high interaction levels.

Cite This Study

Sánchez‐Magraner et al. (2020) studied this question.

synapsesocial.com/papers/6ab08995863a646951ebf42c https://doi.org/10.1158/0008-5472.can-20-1117

View Full Paper

Ask AI

Bookmark

Implication

Translational cohort study reveals reduced survival in metastatic lung cancer patients with low PD-1/PD-L1 binding, indicating physical checkpoint interaction predicts immunotherapy response.

High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment

Discussion

Member takes

Implication

Key Points

Cite This Study

High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider